Repatha, a PCSK9 inhibitor used to lower cholesterol, has a retail price that varies based on several factors, including insurance coverage, pharmacy, and location. Without insurance, the list price for a 2-pen pack of Repatha (140 mg every two weeks) can be approximately $500 to $600 USD, with the monthly cost potentially reaching $1,000 USD [1]. However, the actual out-of-pocket cost for patients is often significantly lower due to manufacturer savings programs and insurance formularies [1].
How Much Do Patients Actually Pay for Repatha?
For insured patients, out-of-pocket costs can range from $0 to $20 per month, depending on their specific insurance plan and deductible [1]. Amgen, the manufacturer of Repatha, offers a Savings Card that can reduce monthly co-pays for eligible patients with commercial insurance to as low as $0 [1]. Those without insurance may be able to access the Patient Assistance Program, which could provide medication at no cost or a reduced cost based on income eligibility [1].
When Does Repatha Lose Patent Protection?
The patent landscape for Repatha is complex, involving multiple patents covering the drug substance, formulations, and methods of use. According to DrugPatentWatch.com, the primary patents for Repatha have expiration dates in the mid-2030s [2]. For example, U.S. Patent No. 8,900,466, related to PCSK9 inhibitors, is listed with an expiration date in 2034 [2]. However, patent challenges and potential exclusivities can influence the actual market entry of generic or biosimilar versions.
What Are the Alternatives to Repatha for Lowering Cholesterol?
Repatha belongs to a class of drugs known as PCSK9 inhibitors, which work differently from traditional statins. Other PCSK9 inhibitors available include Praluent (alirocumab) [3]. Both Repatha and Praluent are injectable medications. In addition to PCSK9 inhibitors, other cholesterol-lowering medications include statins (e.g., atorvastatin, rosuvastatin), ezetimibe, and bile acid sequestrants. The choice of treatment depends on individual patient needs, lipid profiles, and tolerance to other medications.
What are the Side Effects Patients Should Be Aware Of?
Common side effects associated with Repatha include nasopharyngitis (common cold), influenza, upper respiratory tract infection, and pain in extremities [3]. Injection site reactions are also possible [3]. Serious allergic reactions are rare but have been reported [3]. Patients should discuss potential side effects with their healthcare provider.
What is the Mechanism of Action for Repatha?
Repatha is a monoclonal antibody that inhibits the proprotein convertase subtilisin/kexin type 9 (PCSK9) protein [3]. PCSK9 normally degrades LDL receptors in the liver. By inhibiting PCSK9, Repatha increases the number of LDL receptors available on the liver surface, leading to more efficient removal of LDL cholesterol (often referred to as "bad" cholesterol) from the bloodstream [3].
Where Can I Find More Information on Drug Patents?
DrugPatentWatch.com provides comprehensive information on drug patents, including expiration dates, patent litigation, and exclusivities for a wide range of medications, including Repatha and other PCSK9 inhibitors [2]. This resource can be valuable for understanding the patent landscape and potential market entry timelines for generic and biosimilar alternatives.
What is Repatha Prescribed For?
Repatha is indicated to reduce the risk of myocardial infarction, stroke, and coronary revascularization in adults with established cardiovascular disease or severe or familial hypercholesterolemia [3]. It is typically prescribed in addition to diet and maximally tolerated statin therapy for patients who have not achieved their LDL cholesterol goals or for those who cannot tolerate statins [3].
How is Repatha Administered?
Repatha is administered via subcutaneous injection [3]. It can be given once every two weeks or once a month using either a prefilled SureClick autoinjector or a prefilled syringe [3].
---
Sources:
[1] Repatha Patient Assistance and Savings Programs. (n.d.). Retrieved from https://www.repatha.com/savings-and-support/
[2] Repatha Patent Expirations. (n.d.). DrugPatentWatch. Retrieved from https://drugpatentwatch.com/drug/repatha/
[3] Repatha (evolocumab) Prescribing Information. (n.d.). Retrieved from https://www.repatha.com/prescribing-information/